No abstract

Abstract:: In the previous years of research, the use of animal model becomes very common for the screening of novel drugs. Animal model represents the complex problems of humans into simplest forms which can be extended further to include the experimental procedure. The most successful models in neuroscience, rats and mice, undoubtedly considered as one of the best models to understand the psychology of mammalian brain and its associated functions involved in various behavioral repertoire. Moreover, recently researchers in behavioral neuroscience are focusing more on the use of aquatic animals especially fish as model species due to their simplicity, and cost effectiveness. Zebrafish (Danio rerio) is a tropical fish from minnow family a genetic structure surprisingly 84 % similar to humans. It is gaining popularity as a model to study the mechanism in behavioral neuropharmacology. Moreover, Zebrafish is having numerous advantages over other rodent models like ease in maintenance due to their small size; breeding power is more, transparency of embryos, overall reduced cost of experimentation and many more. Nowadays, it is considered as an ideal model to study the neurobehavioral aspects with relevance to humans. It is also used in varieties of scientific studies like genetics, neuroscience, pharmacology, and toxicology. In this manuscript, we have described the feasibility and importance of Zebrafish as a model for the screening of novel drugs for different neurological disorders.

No abstract

Antibiotic abuse in hospitals, animal feed, and the food industry for decades has resulted in an alarming increase in antibiotic-resistant microbes. Antibiotic-resistant infections kill 700,000 people every year, and if the current trend continues, 10 million deaths are anticipated by 2050. To combat these life-threatening diseases, new antimicrobials must be discovered and developed quickly. Bacteriocins, a viable alternative to antibiotics, are ribosomally synthesized, bactericidal active proteins produced by certain bacteria and have the potential to substitute antibiotics to combat multidrug-resistant pathogens. To harness the full potential of these natural antimicrobials, their limitations such as sensitivity to proteolytic enzymes, a restricted antibacterial spectrum, a high dosage requirement, and low yield must be overcome first. This review discusses the use of combinatorial therapy to improve and broaden the antibacterial activity of bacteriocins while reducing the risk of resistance development, which is critical for their use as therapeutics and food preservatives.